Clodronate inhibits angiogenesis in vitro and in vivo

被引：2

作者：

Ribatti, D. ^{[1
]}

Maruotti, N. ^{[2
]}

Nico, B. ^{[1
]}

Longo, V. ^{[1
]}

Mangierv, D. ^{[1
]}

Vacca, A. ^{[3
]}

Cantatore, F. P. ^{[2
]}

机构：

[1] Univ Bari, Sch Med, Dept Human Anat & Histol, I-70124 Bari, Italy

[2] Univ Foggia Med Sch, Dept Rheumatol, Foggia, Italy

[3] Univ Bari, Sch Med, Dept Biomed Sci & Clin Oncol, I-70124 Bari, Italy

来源：

ONCOLOGY REPORTS | 2008年 / 19卷 / 05期

关键词：

antiangiogenesis; bisphosphonate; chorioallantoic membrane; clodronate; endothelial cells;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The effects of amino-bisphosphonate clodronate on endothelial cell functions involved in angiogenesis, namely proliferation and morphogenesis on matrigel were tested in vitro, whereas its effects on angiogenesis were studied in vivo. This was performed by using the chick embryo chorioallantoic membrane (CAM) assay. In vitro, clodronate inhibited the endothelial cell proliferation in a dose-dependent fashion, peaking at 30 mu M. At the same concentration, clodronate inhibited the fibroblast growth factor-2 (FGF-2)-induced capillary-like tube formation in the morphogenesis assay on matrigel. In vivo, when tested with the CAM assay, clodronate again displayed the capability to inhibit FGF-2-induced angiogenesis. Overall, these results suggest that antiangiogenesis by clodronate can be used to treat a wide spectrum of angiogenesis-dependent diseases, including certain chronic inflammatory diseases and cancer.

引用

页码：1109 / 1112

页数：4

共 21 条

[1] Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates:: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs [J].

Benford, HL ;

Frith, JC ;

Auriola, S ;

Mönkkönen, J ;

Rogers, MJ .

MOLECULAR PHARMACOLOGY, 1999, 56 (01) :131-140

[2] Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death -: Evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt [J].

Bezzi, M ;

Hasmim, M ;

Bieler, G ;

Dormond, O ;

Rüegg, C .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (44) :43603-43614

[3] Developments in the therapeutic applications of bisphosphonates [J].

Brown, DL ;

Robbins, R .

JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (07) :651-660

[4]

FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182

[5] ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].

FOLKMAN, J .

NATURE MEDICINE, 1995, 1 (01) :27-31

[6]

Fournier P, 2002, CANCER RES, V62, P6538

[7] Antitumor effects of bisphosphonates [J].

Green, JR .

CANCER, 2003, 97 (03) :840-847

[8] A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis [J].

Hamma-Kourbali, Y ;

Di Benedetto, M ;

Ledoux, D ;

Oudar, O ;

Leroux, Y ;

Lecouvey, M ;

Kraemer, M .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 310 (03) :816-823

[9] QUANTIFICATION OF CELLS CULTURED ON 96-WELL PLATES [J].

KUENG, W ;

SILBER, E ;

EPPENBERGER, U .

ANALYTICAL BIOCHEMISTRY, 1989, 182 (01) :16-19

[10] Neridronate inhibits angiogenesis in vitro and in vivo [J].

Ribatti, D. ;

Nico, B. ;

Mangieri, D. ;

Maruotti, N. ;

Longo, V. ;

Vacca, A. ;

Cantatore, F. P. .

CLINICAL RHEUMATOLOGY, 2007, 26 (07) :1094-1098

← 1 2 3 →